A pivotal Phase 3 clinical trial in pancreatic cancer evaluating IMM-1-104
Latest Information Update: 25 Mar 2025
At a glance
- Drugs IMM 1 104 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 25 Mar 2025 New trial record
- 20 Mar 2025 According to Immuneering media release, company plans to initiate a pivotal Phase 3 clinical trial in pancreatic cancer